DeepMed Research

The Gynecologic Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1970-01-01

Employees: 11

Market Cap: -

Website: http://www.gog.org

Clinical Trials

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2006-12-05

Last Posted Date: 2019-03-20

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 28

Registration Number: NCT00407758

Locations: 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 13 locations

Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: trabectedin

First Posted Date: 2006-09-21

Last Posted Date: 2017-12-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 20

Registration Number: NCT00379145

Locations: 🇺🇸
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
🇺🇸
Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

and more 29 locations

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Phase 2

Withdrawn

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

First Posted Date: 2006-08-30

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00369954

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Phase 1

Completed

Conditions: Neutropenia
Infectious Disorder
Stage IV Ovarian Cancer
Fallopian Tube Carcinoma
Ovarian Carcinosarcoma
Primary Peritoneal Carcinoma
Stage III Ovarian Cancer

Interventions: Procedure: Adjuvant Therapy
Drug: Carboplatin
Drug: Paclitaxel
Biological: Pegfilgrastim

First Posted Date: 2006-07-14

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 43

Registration Number: NCT00352300

Locations: 🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Lake University Ireland Cancer Center, Mentor, Ohio, United States

and more 8 locations

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Recurrent Cervical Carcinoma
Cervical Small Cell Carcinoma
Cervical Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Other: Laboratory Biomarker Analysis

First Posted Date: 2006-04-03

Last Posted Date: 2019-01-08

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 37

Registration Number: NCT00309959

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 23 locations

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

Phase 2

Completed

Conditions: Osteoporosis
Ovarian Carcinoma
Hereditary Breast and Ovarian Cancer Syndrome

Interventions: Other: Laboratory Biomarker Analysis
Drug: Zoledronic Acid

First Posted Date: 2006-03-22

Last Posted Date: 2020-03-24

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 160

Registration Number: NCT00305695

Locations: 🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of California San Diego, San Diego, California, United States

and more 92 locations

Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2006-01-13

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 66

Registration Number: NCT00276796

Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass

Not Applicable

Conditions: Ovarian Cancer
Fallopian Tube Cancer

First Posted Date: 2005-10-13

Last Posted Date: 2010-02-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 2000

Registration Number: NCT00238342

Locations: 🇺🇸
Bayfront Medical Center, St. Petersburg, Florida, United States
🇺🇸
Northwest Community Hospital, Arlington Heights, Illinois, United States
🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States

and more 104 locations

Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Adenosquamous Carcinoma
Recurrent Cervical Carcinoma
Cervical Adenocarcinoma
Cervical Small Cell Carcinoma
Cervical Squamous Cell Carcinoma

Interventions: Procedure: Conventional Surgery

First Posted Date: 2005-09-22

Last Posted Date: 2015-05-29

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 38

Registration Number: NCT00217633

Locations: 🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 36 locations

Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: topotecan hydrochloride

First Posted Date: 2005-06-14

Last Posted Date: 2018-07-24

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 81

Registration Number: NCT00114166

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Tufts-NEMC Cancer Center, Boston, Massachusetts, United States

and more 75 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy